Today, we learned from the State Drug Administration that in 2025, the number of innovative drugs approved for marketing in China reached 76, far exceeding the 48 in 2024, a record high. Furthermore, in 2025, the total amount of foreign authorized transactions for innovative drugs in China exceeded 130 billion US dollars, and the number of authorized transactions exceeded 150, which also reached a record high. According to information, the State Drug Administration approved 76 innovative drugs for marketing in 2025, including 47 chemicals, 23 biological products, and 6 traditional Chinese medicines. Of the 47 chemical drugs, 38 are domestically produced innovative drugs, and 9 are imported innovative drugs, accounting for 80.85%; of the 23 biological products, 21 are domestically produced innovative drugs and 2 are imported innovative drugs, accounting for 91.30% of domestic innovative drugs.

Today, we learned from the State Drug Administration that in 2025, the number of innovative drugs approved for marketing in China reached 76, far exceeding the 48 in 2024, a record high. Furthermore, in 2025, the total amount of foreign authorized transactions for innovative drugs in China exceeded 130 billion US dollars, and the number of authorized transactions exceeded 150, which also reached a record high. According to information, the State Drug Administration approved 76 innovative drugs for marketing in 2025, including 47 chemicals, 23 biological products, and 6 traditional Chinese medicines. Of the 47 chemical drugs, 38 are domestically produced innovative drugs, and 9 are imported innovative drugs, accounting for 80.85%; of the 23 biological products, 21 are domestically produced innovative drugs and 2 are imported innovative drugs, accounting for 91.30% of domestic innovative drugs.